Page 1 | Search Results | Blood | American Society of Hematology

1-16 of 16

Sort by

Sort Order Select

Journal Articles

Investigation Of Fresh Tissue and Effusion Samples From Immunocompromised Hematologic Patients Suspected For Invasive Fungal Infection With An Aspergillus- specific PCR Is a Promising Tool For Identifying Invasive Aspergillosis

Blood (2013) 122 (21): 4552.

https://doi.org/10.1182/blood.V122.21.4552.4552

Published: 2013

Journal Articles

Sorafenib Monotherapy Is Effective In Relapsed and RefractoryFlt3-ITD Positive Acute Myeloid Leukemia, Particularly After Allogenic Stem Cell Transplantation

Blood (2010) 116 (21): 3314.

https://doi.org/10.1182/blood.V116.21.3314.3314

Published: 2010

Journal Articles

Compassionate Use of Sorafenib in Relapsed and Refractory Flt3-ITD Positive Acute Myeloid Leukemia.

Stephan Metzelder, Sebastian Scholl, MD, Kröger Matthias, Andreas Reiter, MD, Ralf G. Meyer, Thomas Heinicke, Aristoteles Giagounidis, Brugger Wolfgang, Mathias Vöhringer, Michael Stadler, MD, Beate Schultheis, Lothar Müller, Mathias Hänel, Andreas Hochhaus, MD, Erich Enghofer, PhD, Andreas Neubauer, Andreas Burchert

Blood (2009) 114 (22): 2060.

https://doi.org/10.1182/blood.V114.22.2060.2060

Published: 2009

Journal Articles

Expression of the miR-17-92 polycistron in chronic myeloid leukemia (CML) CD34 + cells

Letizia Venturini, Karin Battmer, Mirco Castoldi, Beate Schultheis, Andreas Hochhaus, Martina U. Muckenthaler, Arnold Ganser, Matthias Eder, Michaela Scherr

Blood (2007) 109 (10): 4399–4405.

https://doi.org/10.1182/blood-2006-09-045104

Published: 2007

Journal Articles

The Polycistronic miRNA Cluster miR-17-92 Is Over-Expressed in Early Phase Chronic Myeloid Leukemia (CML) CD34+ Cells.

Letizia Venturini, PhD, Karin Battmer, Mirco Castoldi, PhD, Beate Schultheis, MD, Andreas Hochhaus, MD, Martina Muckenthaler, PhD, Arnold Ganser, MD, Matthias Eder, MD, Michaela Scherr, PhD

Blood (2006) 108 (11): 741.

https://doi.org/10.1182/blood.V108.11.741.741

Published: 2006

Journal Articles

Enhanced sensitivity to inhibition of SHP2, STAT5, and Gab2 expression in chronic myeloid leukemia (CML)

Michaela Scherr, Anuhar Chaturvedi, Karin Battmer, Iris Dallmann, Beate Schultheis, Arnold Ganser, Matthias Eder

Blood (2006) 107 (8): 3279–3287.

https://doi.org/10.1182/blood-2005-08-3087

Published: 2006

Journal Articles

Transient Response to Imatinib in an Atypical Chronic Myeloproliferative Disease Associated with ins(9;4)(q34;q21q31) and a CDK5RAP2-PDGFRA Fusion Gene.

Christoph Walz, Beate Schultheis, Georgia Metzgeroth, Claudia Schoch, Claire Curtis, Eva Lengfelder, Torsten Haferlach, Ute Berger, Andreas Hochhaus, Rüdiger Hehlmann, Nicholas C.P. Cross, Andreas Reiter

Blood (2005) 106 (11): 3281.

https://doi.org/10.1182/blood.V106.11.3281.3281

Published: 2005

Journal Articles

Widespread occurrence of the JAK2 V617F mutation in chronic myeloproliferative disorders

Blood (2005) 106 (6): 2162–2168.

https://doi.org/10.1182/blood-2005-03-1320

Published: 2005

Journal Articles

Analysis of total phosphotyrosine levels in CD34 + cells from CML patients to predict the response to imatinib mesylate treatment

Beate Schultheis, Richard Szydlo, François X. Mahon, Jane F. Apperley, Junia V. Melo

Blood (2005) 105 (12): 4893–4894.

https://doi.org/10.1182/blood-2005-01-0210

Published: 2005

Journal Articles

Differential Sensitivity of Normal and CML-Derived CD34+ Cells to Inhibition of SHP-2 Gene Expression by RNA Interference (RNAi).

Michaela Scherr, PhD, Karin Battmer, Anuhar Chaturvedi, Beate Schultheis, MD, Arnold Ganser, MD, Matthias Eder, MD

Blood (2004) 104 (11): 2778.

https://doi.org/10.1182/blood.V104.11.2778.2778

Published: 2004

Journal Articles

CML with E8A2 BCR-ABL Fusion: The Fourth Breakpoint Cluster Region?.

Shadmehr Demehri, Thoralf Lange, MD, Peter Paschka, MD, Susan Branford, MD, Tamio Koizumi, MD, Takeshi Sugimoto, MD, Lay-Cheng Lim, MD, Beate Schultheis, MD, Thomas Kegel, MD, Giovanni Martinelli, MD, Andreas Hochhaus, MD, Brian J. Druker, MD, Michael W. Deininger, MD, PhD

Blood (2004) 104 (11): 1018.

https://doi.org/10.1182/blood.V104.11.1018.1018

Published: 2004

Journal Articles

Synergism between 17-AAG and Imatinib in Imatinib-Resistant CML Cells: Inhibition of P-Glycoprotein by 17-AAG as a New Mechanism of Increasing Imatinib Activity.

Aleksandar Radujkovic, Moritz Schad, Julian Topaly, MD, Stephanie Laufs, PhD, Anna Jauch, MD, Beate Schultheis, MD, Junia V. Melo, MD, Anthony D. Ho, MD, Stefan Fruehauf, MD, W. Jens Zeller, MD

Blood (2004) 104 (11): 2094.

https://doi.org/10.1182/blood.V104.11.2094.2094

Published: 2004

Journal Articles

Allorestricted cytotoxic T cells specific for human CD45 show potent antileukemic activity

Persis J. Amrolia, Steven D. Reid, Liquan Gao, Beate Schultheis, Gianpietro Dotti, Malcolm K. Brenner, Junia V. Melo, John M. Goldman, Hans J. Stauss

Blood (2003) 101 (3): 1007–1014.

https://doi.org/10.1182/blood-2002-02-0525

Published: 2003

Journal Articles

Overexpression of SOCS-2 in advanced stages of chronic myeloid leukemia: possible inadequacy of a negative feedback mechanism

Beate Schultheis, Melina Carapeti-Marootian, Andreas Hochhaus, Andreas Weiβer, John M. Goldman, Junia V. Melo

Blood (2002) 99 (5): 1766–1775.

https://doi.org/10.1182/blood.V99.5.1766

Published: 2002

Journal Articles

Selection and characterization of BCR-ABL positive cell lines with differential sensitivity to the tyrosine kinase inhibitor STI571: diverse mechanisms of resistance

François Xavier Mahon, Michael W. N. Deininger, Beate Schultheis, Jérome Chabrol, Josy Reiffers, John M. Goldman, Junia V. Melo

Blood (2000) 96 (3): 1070–1079.

https://doi.org/10.1182/blood.V96.3.1070

Published: 2000

Journal Articles

Molecular heterogeneity in complete cytogenetic responders after interferon-α therapy for chronic myelogenous leukemia: low levels of minimal residual disease are associated with continuing remission

Andreas Hochhaus, Andreas Reiter, Susanne Saußele, Anja Reichert, Michael Emig, Jaspal Kaeda, Beate Schultheis, Ute Berger, Patricia C. A. Shepherd, Norman C. Allan, Rüdiger Hehlmann, John M. Goldman, Nicholas C. P. Cross

Blood (2000) 95 (1): 62–66.

https://doi.org/10.1182/blood.V95.1.62

Published: 2000

NARROW

Investigation Of Fresh Tissue and Effusion Samples From Immunocompromised Hematologic Patients Suspected For Invasive Fungal Infection With An Aspergillus- specific PCR Is a Promising Tool For Identifying Invasive Aspergillosis

Sorafenib Monotherapy Is Effective In Relapsed and RefractoryFlt3-ITD Positive Acute Myeloid Leukemia, Particularly After Allogenic Stem Cell Transplantation

Compassionate Use of Sorafenib in Relapsed and Refractory Flt3-ITD Positive Acute Myeloid Leukemia.

Expression of the miR-17-92 polycistron in chronic myeloid leukemia (CML) CD34 + cells

The Polycistronic miRNA Cluster miR-17-92 Is Over-Expressed in Early Phase Chronic Myeloid Leukemia (CML) CD34+ Cells.

Enhanced sensitivity to inhibition of SHP2, STAT5, and Gab2 expression in chronic myeloid leukemia (CML)

Transient Response to Imatinib in an Atypical Chronic Myeloproliferative Disease Associated with ins(9;4)(q34;q21q31) and a CDK5RAP2-PDGFRA Fusion Gene.

Widespread occurrence of the JAK2 V617F mutation in chronic myeloproliferative disorders

Analysis of total phosphotyrosine levels in CD34 + cells from CML patients to predict the response to imatinib mesylate treatment

Differential Sensitivity of Normal and CML-Derived CD34+ Cells to Inhibition of SHP-2 Gene Expression by RNA Interference (RNAi).

CML with E8A2 BCR-ABL Fusion: The Fourth Breakpoint Cluster Region?.

Synergism between 17-AAG and Imatinib in Imatinib-Resistant CML Cells: Inhibition of P-Glycoprotein by 17-AAG as a New Mechanism of Increasing Imatinib Activity.

Allorestricted cytotoxic T cells specific for human CD45 show potent antileukemic activity

Overexpression of SOCS-2 in advanced stages of chronic myeloid leukemia: possible inadequacy of a negative feedback mechanism

Selection and characterization of BCR-ABL positive cell lines with differential sensitivity to the tyrosine kinase inhibitor STI571: diverse mechanisms of resistance

Molecular heterogeneity in complete cytogenetic responders after interferon-α therapy for chronic myelogenous leukemia: low levels of minimal residual disease are associated with continuing remission

Email alerts

ASH Publications

American Society of Hematology

Email alerts

ASH Publications

American Society of Hematology

This Feature Is Available To Subscribers Only